Taenzer V, Volkhardt V
AJR Am J Roentgenol. 1979 Jan;132(1):55-8. doi: 10.2214/ajr.132.1.55.
Two new intravenous cholegraphic agents, iotroxate and iodoxamate, hold a lower general toxicity, lower protein binding, and claim a higher rate of biliary excretion. Both compounds proved to be equally effective in opacifying the gallbladder and the bile ducts in a double-blind clinical study comprising 400 cases. Iotroxate gave significantly earlier good or adequate visualization as a result of its higher excretion rate by the liver (P less than 0.05). Side effects were observed in fewer patients in the iotroxate group (11.6%) compared with the iodoxamate group (16.4%, P greater than 0.05). In a second double-blind study, an iotroxage group of 97 patients who received two thirds of the overall content of iodine (3.6 g) was compared with a group of 98 patients, who received ioglycamate (5.3 g). Visualization was equal in the two groups, while side effects were significantly reduced to 10.3% in the iotroxate group against 20.4% (P less than 0.05). The higher biliary clearance of iotroxate permits a reduction of the amount of iodine.
两种新型静脉胆囊造影剂，碘托酸和碘多酸，具有较低的全身毒性、较低的蛋白结合率，并宣称具有较高的胆汁排泄率。在一项包括400例患者的双盲临床研究中，这两种化合物在使胆囊和胆管显影方面被证明同样有效。由于碘托酸通过肝脏的排泄率较高，其能显著更早地获得良好或足够的显影效果（P小于0.05）。与碘多酸组（16.4%，P大于0.05）相比，碘托酸组出现副作用的患者较少（11.6%）。在第二项双盲研究中，将接受碘总量三分之二（3.6克）的97例碘托酸组患者与接受碘甘氨酸盐（5.3克）的98例患者进行比较。两组的显影效果相同，而碘托酸组的副作用显著降低至10.3%，而另一组为20.4%（P小于0.05）。碘托酸较高的胆汁清除率使得碘用量得以减少。
